Skip to content

PTEN-AKT-FOXO3 Gene Expression Relation With Low-ovarian Reserve in Endometriomas

RELATIONSHIP OF LOW-OVER RESERVE WITH PTEN-AKT-FOXO3 GENE EXPRESSION IN THE PRESENCE OF ENDOMETRIOMAS

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04058912
Enrollment
60
Registered
2019-08-16
Start date
2019-05-27
Completion date
2020-06-30
Last updated
2019-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Reserve, Endometrioma, PTEN-AKT-FOXO3 Gene Expression

Brief summary

In this study, we aimed to investigate the relationship between PTEN-AKT-FOXO3 gene expression and decrease in ovarian reserve in the presence of endometrioma and other benign ovarian pathologies.

Detailed description

It is known that the presence of endometrioma negatively affects ovarian reserve. The development of endometriosis and the effect of the presence of endometrioma on ovarian reserve due to decreased PTEN expression are considered. This study was designed to compare ovarian PTEN-AKT-FOXO3 gene expression and ovarian reserve in patients with underwent surgery caused by endometrioma and those who had ovarian pathology due to other benign causes and PTEN-AKT-FOXO3 gene expression level will be evaluated by RT-PCR analysis.

Interventions

GENETICPTEN-AKT-FOXO3 Gene Expression

In the patient and patient control groups, 0.5 mm tissue strip will be removed for pathology from the cyst wall removed during surgery. and tissue samples will be stored in phosphate buffered saline at -80 C and PTEN-AKT-FOXO3 gene expression level will be evaluated by RT-PCR analysis.

Sponsors

Uludag University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years

Inclusion criteria

* 1\) To be in the range of 18-40 years 2) Patients with an operation indication with \>=5 cm endometrioma 3) Patients with operation plan due to non-endometrioma ovarian pathologies

Exclusion criteria

* 1)Patients over the age of 40 2)Patients with suspected malignancy 3)Follow-up patients without indications for operation

Design outcomes

Primary

MeasureTime frameDescription
PTEN AKT FOXO3 gene expression30 minutesIn the patient and patient control groups, 0.5 mm tissue strip will be removed for pathology from the cyst wall removed during surgery. and tissue samples will be stored in phosphate buffered saline at -80 C and PTEN-AKT-FOXO3 gene expression level will be evaluated by RT-PCR analysis.

Countries

Turkey (Türkiye)

Contacts

Primary ContactHAMZA F SEN, MD
hamzafurkansen@yahoo.com+90 544 3939159
Backup ContactIsil Kasapoglu, MD
kasapogluisil@hotmail.com+905305455848

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026